Paragon 28

Paragon 28 EPS

Delisted

The Earnings per Share (EPS) of Paragon 28 (FNA) as of Nov 3, 2026 is -0.66 USD. In the previous year, Earnings per Share (EPS) was -0.58 USD — a change of 13.54% (lower).

EPS

-0.66USD

YoY

13.54%

Last updated:

Earnings per Share (EPS) of Paragon 28 is 2024 -0.66 USD. Earnings per Share (EPS) of Paragon 28 was 2023 -0.58 USD. It decreases by 13.54% lower compared to the previous year.

The Paragon 28 EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2021
-0.18 USD
Jan 1, 2022
-0.87 USD
Jan 1, 2023
-0.58 USD
Jan 1, 2024
-0.66 USD
Jan 1, 2025 (e)
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
-0.24 USD
Jan 1, 2028 (e)
-0.06 USD
The Paragon 28 EPS history
YEAREPSYoY
est-0.06USD-75.00%
est-0.24USD—
est0.00USD—
est0.00USD-100.00%
-0.66USD+13.54%
-0.58USD-33.28%
-0.87USD+383.32%
-0.18USD-548.84%
0.04USD-21.90%
0.05USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Paragon 28 Stock analysis

What does Paragon 28 do? Paragon 28, Inc. generates revenue through the development, distribution, and sale of medical devices in the foot and ankle orthopedic implant market. The company offers a comprehensive portfolio including plates and plating systems, screws, staples, and nails for fracture fixation, bunion and hammertoe procedures, ankle treatments, flatfoot correction, and Charcot foot solutions. Its surgical solutions consist of 75 product systems with approximately 9,200 SKUs, comprising 6,800 implants, 1,400 instruments, and 1,000 disposables. Hospitals and orthopedic surgeons purchase these products for patient care and surgical procedures. The company’s product families address all foot and ankle procedures, including progressive collapsing foot deformity (PCDF) and orthobiologics. Surgical implants, disposables, and instrumentation are sold directly to healthcare providers. The firm’s focus on specialized foot and ankle solutions allows it to serve a niche segment within the orthopedic implant marketplace. Paragon 28’s portfolio includes approximately 6,800 implants, 1,400 instruments, and 1,000 disposable SKUs, providing tailored options for diverse surgical needs. Paragon 28, Inc. operates within the orthopedic implant industry, targeting hospitals and surgical centers specializing in foot and ankle care. Its products are designed for specific anatomical and surgical requirements, with sizes and configurations varying to fit individual patient needs. The company’s revenue is derived from the sale of its extensive product range, including surgical implants, disposables, and instrumentation, to healthcare providers who perform foot and ankle procedures. Paragon 28 is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Paragon 28 stock

Earnings per Share (EPS) of Paragon 28 is -0.66 USD in 2024.

Earnings per Share (EPS) of Paragon 28 changed from -0.58 USD to -0.66 USD, representing a 13.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Paragon 28 since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Paragon 28

All Key Metrics — Paragon 28